UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Journal of the European Academy of Dermatology and Venereology, 2021-05, Vol.35 (5), p.1152-1160

2021

Volltextzugriff (PDF)

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis

Journal of the European Academy of Dermatology and Venereology, 2022-06, Vol.36 (6), p.797-806

2022

Volltextzugriff (PDF)

Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data

Value in health, 2014-05, Vol.17 (3), p.A288-A288

2014

Volltextzugriff (PDF)

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

British journal of dermatology (1951), 2020-03, Vol.182 (3), p.605-617

2020

Volltextzugriff (PDF)

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British journal of dermatology (1951), 2021-12, Vol.185 (6), p.1135-1145

2021

Volltextzugriff (PDF)

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

Journal of the European Academy of Dermatology and Venereology, 2020-02, Vol.34 (2), p.301-309

2020

Volltextzugriff (PDF)

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

British journal of dermatology (1951), 2018-08, Vol.179 (2), p.320-328

2018

Volltextzugriff (PDF)

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

British journal of dermatology (1951), 2020-04, Vol.182 (4), p.880-888

2020

Volltextzugriff (PDF)

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

Journal of the European Academy of Dermatology and Venereology, 2015-10, Vol.29 (10), p.2002-2010

2015

Volltextzugriff (PDF)

LB946 Spesolimab controls chronic inflammation in GPP

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S165-S165

2024

Volltextzugriff (PDF)

605 Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion

Journal of investigative dermatology, 2020-07, Vol.140 (7), p.S82-S82

2020

Volltextzugriff (PDF)

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.306-314

2019

Volltextzugriff (PDF)

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Journal of the European Academy of Dermatology and Venereology, 2021-04, Vol.35 (4), p.919-927

2021

Volltextzugriff (PDF)

Chronic lichen sclerosus successfully treated with intralesional adalimumab

British journal of dermatology (1951), 2016-03, Vol.174 (3), p.687-689

2016

Volltextzugriff (PDF)

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Journal of the European Academy of Dermatology and Venereology, 2022-10, Vol.36 (10), p.1774-1783

2022

Volltextzugriff (PDF)

Brodalumab 用于对乌司奴单抗应答不足的患者

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.e53-e53

2019

Volltextzugriff (PDF)

434 Baseline IL-22 expression in atopic dermatitis patients stratifies therapeutic responses to fezakinumab

Journal of investigative dermatology, 2018-05, Vol.138 (5), p.S74-S74

2018

Volltextzugriff (PDF)

Pseudoxanthoma elasticum: an update

Dermatology (Basel), 1999-01, Vol.199 (1), p.3

1999

Volltextzugriff (PDF)

Brodalumab in patients who had inadequate response to ustekinumab

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.e40-e40

2019

Volltextzugriff (PDF)

Brodalumab 用于对乌司奴单抗应答不足的患者

British journal of dermatology (1951), 2019-02, Vol.180 (2), p.e53-e53

2019

Volltextzugriff (PDF)

A study of the drug tildrakizumab in psoriasis patients

British journal of dermatology (1951), 2020-03, Vol.182 (3), p.e100-e100

2020

Volltextzugriff (PDF)

一项在银屑病患者中开展的 tildrakizumab 药物研究

British journal of dermatology (1951), 2020-03, Vol.182 (3), p.e113-e113

2020

Volltextzugriff (PDF)

一项在银屑病患者中开展的 tildrakizumab 药物研究

British journal of dermatology (1951), 2020-03, Vol.182 (3)

2020

Volltextzugriff (PDF)

279 Reduced pruritus and signs of atopic dermatitis in phase 3 trials with a nonsteroidal topical phosphodiesterase inhibitor, crisaborole

Journal of investigative dermatology, 2016-05, Vol.136 (5), p.S49-S49

2016

Volltextzugriff (PDF)

Tolérance à long terme de l’ixékizumab chez des patients atteints de psoriasis modéré à sévère : résultats de plus de 17 000 patients-années d’exposition

Annales de dermatologie et de vénéréologie, 2019-12, Vol.146 (12), p.A351-A352

2019

Volltextzugriff (PDF)

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(29)

Sprache

Erscheinungsjahr

n.n

Thema

Dermatology
(14)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Psoriasis
(12)
Humans
(11)
Monoclonal Antibodies
(9)
Psoriasis - Drug Therapy
(8)
Severity Of Illness Index
(7)
Patients
(6)
Treatment Outcome
(6)
Clinical Trials
(5)
Immunotherapy
(5)
Adult
(4)
Double-Blind Method
(4)
Original
(4)
Safety
(4)
Aged
(3)
Antibodies, Monoclonal, Humanized
(3)
Randomized Controlled Trials As Topic
(3)
Skin - Pathology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Long‐term safety and efficacy of a fixed‐combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate‐to‐severe plaque psoriasis: phase 3 open‐label study

Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis

Psychometric Evaluation Of The Psoriasis Symptom Diary Using Phase 3 Trial Data

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3

Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials

Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey

LB946 Spesolimab controls chronic inflammation in GPP

605 Long-term management of moderate-to-severe plaque psoriasis: Maintenance of treatment success following cessation of halobetasol propionate 0.01%/tazarotene 0.045% lotion

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials

Time to relapse after tildrakizumab withdrawal in patients with moderate‐to‐severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

Chronic lichen sclerosus successfully treated with intralesional adalimumab

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Brodalumab 用于对乌司奴单抗应答不足的患者

434 Baseline IL-22 expression in atopic dermatitis patients stratifies therapeutic responses to fezakinumab

Pseudoxanthoma elasticum: an update

Brodalumab in patients who had inadequate response to ustekinumab

Brodalumab 用于对乌司奴单抗应答不足的患者

A study of the drug tildrakizumab in psoriasis patients

一项在银屑病患者中开展的 tildrakizumab 药物研究

一项在银屑病患者中开展的 tildrakizumab 药物研究

279 Reduced pruritus and signs of atopic dermatitis in phase 3 trials with a nonsteroidal topical phosphodiesterase inhibitor, crisaborole

Tolérance à long terme de l’ixékizumab chez des patients atteints de psoriasis modéré à sévère : résultats de plus de 17 000 patients-années d’exposition

Suchergebnisse filtern